On April 6, 2018 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, reported that it will present two posters summarizing preclinical research with its MAGE-A4 and MAGE-A10 SPEAR T-cells at the upcoming AACR (Free AACR Whitepaper) meeting at McCormick Place in Chicago, Illinois (Press release, Adaptimmune, APR 6, 2018, View Source;p=RssLanding&cat=news&id=2341397 [SID1234525200]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Session, date, time, and location (for both posters):

Session Category (Title): Clinical Research (Adoptive Cell Therapy 2)
Date: Monday Apr 16, 2018
Time: 1:00 PM – 5:00 PM (CDT)
Location: McCormick Place South, Exhibit Hall A, Poster Section 24
Poster 1 – MAGE-A4

Title: Affinity-enhanced T-cell receptor (TCR) for adoptive T-cell therapy targeting MAGE-A4
Poster Board Number: 21
Permanent Abstract Number: 2562
Poster 2 – MAGE-A10

Title: Selection of affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE‑A10
Poster Board Number: 23
Permanent Abstract Number: 2564
Adaptimmune will also have a booth (#3700) in the Exhibit Hall.